Celltrion’s Vegzelma listed on prescription of 10 private US insurers

In its first direct sales of medicine in American market, the company will expand its local networks and boost its market share

Celltrion’s Vegzelma listed on prescription of 10 private US insurers
Dae-Kyu Ahn 1
2023-08-23 11:50:10 powerzanic@hankyung.com
Bio & Pharma


South Korea’s Celltrion Healthcare Co. announced on Wednesday that it has signed contracts with 10 insurance providers in the US to boost the prescription of Vegzelma (active ingredient: bevacizumab), a biosimilar to the anti-cancer drug Avastin. 
This move could make the drug accessible to nearly a third of the US population. One of the 10 insurers is in the nation's top five.  

“We are in favorable negotiations with other insurance providers, and we are actively ramping up commercial activities to achieve coverage for over 60% of the US population by early next year,” a Celltrion Healthcare source said.

Celltrion Healthcare has been investing in a targeted commercial strategy this year, enhancing its direct sales capabilities in the US through the recruitment of specialized personnel. In addition, the company is building key relationships with influential stakeholders in the US healthcare market, including insurance companies and group purchasing organizations (GPOs).

This expanding sales network will also serve as a springboard for future products. Notably, the company has its eyes set on Zymfentra, the name of RemsimaSC in the US, which contains infliximab as an active ingredient and is currently under the US approval process.

Write to Dae-Kyu Ahn at powerzanic@hankyung.com

S.Korea's Celltrion Healthcare launches Vegzelma in US

S.Korea's Celltrion Healthcare launches Vegzelma in US

South Korea's Celltrion Healthcare Co. on Monday said it launched on the US market Vegzelma, a biosimilar of Bevacizumab, a medication for colorectal and breast cancer sold under the name Avastin.The company has prepared for the launch since September last year, when it received approval to se

Celltrion Healthcare launches anti-cancer biosimilar Vegzelma in Japan

Celltrion Healthcare launches anti-cancer biosimilar Vegzelma in Japan

Celltrion's Vegzelma Celltrion Healthcare Co. Ltd. said on Thursday that it launched Vegzelma, a biosimilar to the anti-cancer drug Avastin (active ingredient: bevacizumab) in Japan.In September last year, Vegzelma obtained marketing approval for metastatic colorectal cancer, non-small cell lun

Celltrion acquires approval to sell Vegzelma in Canada

Celltrion acquires approval to sell Vegzelma in Canada

Celltrion's Vegzelma South Korea's biosimilar heavyweight Celltrion Inc. has obtained permission from the Canadian health ministry to sell anticancer biosimilar Vegzelma, the company said on Thursday.Vegzelma is a biosimilar to Avastin (ingredient name Bevacizumab) used to cure metastatic direc

Celltrion wins sales approval for biosimilar Vegzelma in Japan

Celltrion wins sales approval for biosimilar Vegzelma in Japan

(Courtesy of Celltrion) Celltrion Inc. secured Japan’s approval for sales of its cancer treatment biosimilar CT-P16, a move to help the South Korean biopharmaceutical giant expand its market presence in Asia.Celltrion said on Tuesday it has won permission from the Ministry of Health, Labo

(* comment hide *}